Our study on the safety of biologics and Janus kinase inhibitors in IBD patients with low cardiovascular risk is published in Crohn’s & Colitis 360. Read the paper.
Our study on the safety of biologics and Janus kinase inhibitors in IBD patients with low cardiovascular risk is published in Crohn’s & Colitis 360. Read the paper.